# NewMed Medical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/newmed-medical-co

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.newmed.cn
- Total disclosed funding: $14M
- Latest round: Series C (Mar 25, 2021)
- Investors on record: 10

## About

NewMed Medical Co., Ltd., based in China, specializes in developing innovative medical devices for cardiac care, focusing on heart valve replacement procedures to enhance patient outcomes and surgical success.Founded in 2015 and headquartered in Shanghai, China, NewMed Medical Co., Ltd. operates in the medical device industry, concentrating on cardiac solutions. The company's journey includes raising a total of CNY 100.000 mn through various funding rounds, with the latest round being a Series B that took place on March 25, 2021. Fortune Capital was among the investors in this round, emphasizing the company's appeal in the investment landscape.NewMed Medical Co., Ltd. offers innovative solutions in cardiac care, particularly in simplifying heart valve replacement procedures. Their product range includes advanced medical devices aimed at minimizing treatment risks and improving surgery success rates. The company caters primarily to hospitals and healthcare providers within the Chinese market while also exploring international applications for their technology. Their commitment to research and collaboration within the academic sphere supports their objective of enhancing patient outcomes through technological advancements.NewMed Medical Co., Ltd. generates revenue through direct sales of their medical devices to healthcare institutions, engaging in B2B transactions with hospitals and clinics. Their pricing strategies are structured to support healthcare providers in the procurement process, with revenue primarily derived from bulk orders and contractual partnerships, ensuring their innovative solutions are effectively delivered to end-users.Looking ahead, NewMed Medical Co., Ltd. is focused on launching new products that enhance cardiac care technologies. Recent funding from the Series B round will facilitate these initiatives, as well as support expansion into additional markets. Specifically, the company aims to target broader international markets, enhancing their presence beyond China by the end of 2023. With a solid foundation in research and product development, NewMed Medical is positioning itself for greater market penetration and continued innovation in the medical device sector.

## Funding rounds

- Series C, Mar 25, 2021 — OrbiMed Advisors, Temasek Holdings, Fortune Capital, YF Capital, Junzi Capital, BioTrack Capital, ChuangVest Ventures, Shanghai Zhangke Lingyi Investment Management Co., LTD
- Series B, Apr 15, 2020, $14M — Fortune Capital
- Series B, Mar 3, 2020 — OrbiMed Advisors
- Series A, Jul 17, 2018 — Junzi Capital, BioTrack Capital
- Series A, Apr 3, 2018 — LYZZ Capital, Tahoe Venture Group

## Investors

- LYZZ Capital (https://capitalatlas.ai/funds/lyzz-capital) — Series A
- Tahoe Venture Group (https://capitalatlas.ai/funds/tahoe-venture-group) — Series A
- Junzi Capital (https://capitalatlas.ai/funds/junzi-capital) — Series A, Series C
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Fortune Capital — Series B, Series C
- Temasek Holdings — Series C
- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series C
- ChuangVest Ventures (https://capitalatlas.ai/funds/chuangvest-ventures) — Series C
- Shanghai Zhangke Lingyi Investment Management Co., LTD — Series C